RALLYBIO CORPORATION Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- RALLYBIO CORPORATION stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $13.00K, a 30.00% increase year-over-year.
- RALLYBIO CORPORATION stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $6.00K, a 66.67% decline year-over-year.
- RALLYBIO CORPORATION stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00.
- RALLYBIO CORPORATION stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $10.00K, a 77.27% decline year-over-year.
- RALLYBIO CORPORATION stock issued during period, value, employee stock purchase plan for fiscal 2023 was $282.00K, a 29.95% increase from fiscal 2022.
- RALLYBIO CORPORATION stock issued during period, value, employee stock purchase plan for fiscal 2022 was $217.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $13.00K S-4/A · filed 2026-08-26 | |
| 2025-12-31 | $6.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $16.00K S-4/A · filed 2026-08-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − S-4/A 6 month · filed 2025-11-06 | |
| 2025-06-30 | $10.00K S-4/A · filed 2026-08-26 | |
| 2024-12-31 | $18.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $62.00K S-4/A · filed 2026-08-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2024-06-30 | $44.00K 10-Q · filed 2025-08-07 | |
| 2023-12-31 | $73.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $282.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2023-06-30 | $209.00K 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $217.00K 10-K · filed 2024-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |